Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors

✍ Scribed by Culine, Stéphane; Theodore, Christine; Farhat, Fadi; Bekradda, Mohammed; Terrier-Lacombe, Marie-Josée; Droz, Jean-Pierre

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 384 KB
• Volume: 61
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199603)61:3<195::aid-jso6>3.0.co;2-6

✦ Synopsis

In order to assess the results of cisplatin-based chemotherapy after primary lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors of the testis, we retrospectively reviewed the longterm outcome of 44 patients who received adjuvant chemotherapy at Institut Gustave Roussy over a 7-year period. Two chemotherapy regimens were sequentially delivered. Twenty-three patients were treated with vinblastine, cyclophosphamide, bleomycin, actinomycin D, and cisplatin (mVAB-6, four cycles), while 21 patients received a combination of etoposide and cisplatin (EP, four cycles). After a median follow-up of 6 years, all patients remain free from progression. The long-term toxicity included retrograde ejaculation in eight patients and severe ototoxicity in two patients. We conclude that four cycles of cisplatin-based chemotherapy for pathological stage I1 testicular cancer resulted in a 100% cure rate with minimal toxicity.